Target Name: SNX21
NCBI ID: G90203
Other Name(s): SNX21 variant 1 | SNX-L | SNXL | Sorting nexin-21 (isoform a) | sorting nexin L | Sorting nexin 21 | Sorting nexin family member 21, transcript variant 1 | SNX21_HUMAN | PP3993 | Sorting nexin-21 | dJ337O18.4 | C20orf161 | Sorting nexin L | sorting nexin family member 21

SNX21: A Promising Drug Target and Biomarker for Cancer

SNX21 is a drug target and a potential biomarker for various diseases, including cancer. SNX21 is a small non-coding RNA (ncRNA) that has been shown to play a role in various cellular processes, including cell adhesion, migration, and survival.

SNX21 is a splicing enhancer, which means it helps guide the formation of RNA molecules during the process of gene expression. It has been shown to regulate the expression of many different genes, including cancer-related genes.

One of the most promising aspects of SNX21 is its potential as a drug target. SNX21 has been shown to interact with several protein molecules, including the transcription factor NF-kappa-B. This suggests that SNX21 may be a useful target for drugs that are designed to inhibit the activity of NF-kappa-B.

SNX21 has also been shown to play a role in the regulation of cellular processes that are important for cancer progression. For example, studies have shown that SNX21 is often expressed in various types of cancer, and that it is associated with poor prognosis in these diseases.

In addition to its potential as a drug target, SNX21 also has potential as a biomarker. Its expression has been shown to be associated with the development and progression of many different diseases, including cancer. This suggests that SNX21 may be a useful biomarker for these diseases, and that it may be a useful target for diagnostic tests.

SNX21 is also a promising target for drug development due to its small size and non-coding nature. This makes it easier to study and develop drugs that specifically target SNX21.

In conclusion, SNX21 is a drug target and a potential biomarker for many different diseases, including cancer. Its ability to interact with the transcription factor NF-kappa-B and its association with cancer-related genes make it a promising target for drugs that are designed to inhibit the activity of NF-kappa-B. Further research is needed to fully understand the role of SNX21 in disease progression and its potential as a drug and biomarker.

Protein Name: Sorting Nexin Family Member 21

Functions: Binds to membranes enriched in phosphatidylinositol 3-phosphate (PtdIns(P3)) and phosphatidylinositol 4,5-bisphosphate. May be involved in several stages of intracellular trafficking

More Common Targets

SNX22 | SNX24 | SNX25 | SNX27 | SNX29 | SNX29P1 | SNX29P2 | SNX3 | SNX30 | SNX31 | SNX32 | SNX33 | SNX4 | SNX5 | SNX6 | SNX7 | SNX8 | SNX9 | SOAT1 | SOAT2 | SOBP | SOCAR | SOCS1 | SOCS2 | SOCS2-AS1 | SOCS3 | SOCS3-DT | SOCS4 | SOCS5 | SOCS5P5 | SOCS6 | SOCS7 | SOD1 | SOD2 | SOD2-OT1 | SOD3 | Sodium channel | Sodium-Glucose Cotransporter (SGLT) | Sodium-potassium-calcium exchanger | SOGA1 | SOGA3 | SOHLH1 | SOHLH2 | Soluble (cytosolic) protein tyrosine phosphatases | Soluble guanylyl cyclase | Solute Carrier Family 12 | Solute carrier family 29 member | Somatostatin receptor | SON | SORBS1 | SORBS2 | SORBS3 | SORCS1 | SORCS2 | SORCS3 | SORCS3-AS1 | SORD | SORD2P | SORL1 | SORT1 | Sorting and assembly machinery complex | Sorting nexin | SOS1 | SOS2 | SOSS complex | SOST | SOSTDC1 | SOWAHA | SOWAHB | SOWAHC | SOWAHD | SOX1 | SOX1-OT | SOX10 | SOX11 | SOX12 | SOX13 | SOX14 | SOX15 | SOX17 | SOX18 | SOX2 | SOX2-OT | SOX21 | SOX21-AS1 | SOX3 | SOX30 | SOX30P1 | SOX4 | SOX5 | SOX5-AS1 | SOX6 | SOX7 | SOX8 | SOX9 | SOX9-AS1 | SP1 | SP100 | SP110 | SP140